OBJECTIVES: Although right heart failure (RVF) is an important issue in the management of patients with left ventricular assist devices (LVADs), the benefits of performing tricuspid valve repair in conjunction with LVAD implantation have not been demonstrated.
INTRODUCTION
Since the introduction of a durable continuous left ventricular assist device (LVAD), survival after LVAD implantation has improved, according to the annual report of the INTEragency Registry for Mechanically Assisted Circulatory Support (INTERMACS) [1] . Implantation of a durable LVAD in patients who are eligible for heart transplantation as well as in those who are not eligible has become a class I treatment, according to a 2012 American Heart Association statement [2] . For these reasons and because of donor shortage, the number of patients requiring long-term support with a LVAD has increased, and analysis of risk factors for longterm survival and associated factors has become a critical issue. Severe right heart failure (RVF) is one risk factor for peri-and postoperative mortality and morbidity in patients undergoing LVAD implantation, with a reported incidence as high as 20-50%.
Among patients undergoing LVAD implantation, 10-15% require implantation of a separate right ventricular support device [3] [4] [5] [6] . Thus, RVF is a contraindication for receiving an implantable LVAD, because it may require the use of a biventricular assist device. Prediction and treatment of RVF are important to improve survival after LVAD implantation. Kormos et al. [5] showed that the right ventricular stroke work index and the ratio of central venous pressure (CVP) to pulmonary capillary wedge pressure (PCWP) are critical predictors of RVF after LVAD implantation and that RVF significantly reduced survival after LVAD implantation. RVF can be induced by secondary pulmonary hypertension in addition to fundamental myocardial deterioration of the right ventricle. Furthermore, secondary tricuspid regurgitation (TR) is common among patients with RVF who undergo LVAD implantation [7] and the presence of TR in the setting of RVF is associated with a poor prognosis [8] .
Although repair of TR in combination with LVAD implantation is not an established approach, recent reports have suggested that concomitant tricuspid valve repair may reduce postoperative RVF and influence early outcomes [9] [10] [11] . In another report, tricuspid valve repair performed in conjunction with mitral surgery significantly improved long-term survival among patients with TR, suggesting that tricuspid valve repair in conjunction with LVAD implantation may influence long-term outcomes [12] . To clarify the benefits and durability of this adjuvant procedure, we analysed the records of patients with moderate-to-severe TR or severe tricuspid annular dilatation >40 mm in diameter who underwent tricuspid valve repair in conjunction with LVAD implantation.
METHODS

Study design
Permission for this retrospective study was granted by the Institutional Review Board of the National Cerebral and Cardiovascular Centre of Osaka, Japan, which waived patient consent. From May 1999 to January 2013, 141 patients at a single institution received LVAD implantation as a bridge to transplantation. Preoperative patient and haemodynamic characteristics are given in Table 1 . All patients were in severe heart failure, with INTERMACS profiles from 1 to 3. One hundred and thirteen had dilated cardiomyopathy, 16 were in the dilated phase of hypertrophic cardiomyopathy, 8 had ischaemic cardiomyopathy and 4 had other causes.
The patients were divided into two groups: those who developed RVF (RVF group, n = 27) and those who did not (non-RVF group, n = 114). RVF was defined as the need for a right ventricular assist device (RVAD) or intravenous inotropic support for longer than 30 days. None of the patients underwent planned RVAD implantation and all were weaned from cardiopulmonary bypass. The use of a RVAD was based on clinical evidence of RVF, including inability to fill the LVAD, inadequate systemic output and elevated CVP after weaning off cardiopulmonary bypass, despite inhaled nitric oxide and administration of multiple inotropes. Use of postoperative intravenous inotropes was based on haemodynamics and end-organ function.
All patients underwent pre-and postoperative echocardiography examinations. TR was graded from 0 to 4 (severe). Follow-up echocardiography was performed at 1, 3, 6, 12, 18 and 24 months after implantation. Right heart catheterization was also performed preoperatively. All other data were collected from medical records and all patients completed the course of followup examinations.
Data analysed included patient characteristics and demographics (age, sex, cause of heart failure and body surface area), baseline haemodynamics (cardiac index, PCWP, mean pulmonary artery pressure, CVP, CVP/PCWP ratio, right ventricular stroke work index and left ventricular ejection fraction), use of an intra-aortic balloon pump or ventilator support and laboratory data. Myocardial core specimens obtained from the left ventricular apex during cannulation of LVAD outflow were examined pathologically with Masson trichrome stain and fibrosis was graded from 0 to 3. The fibrosis score was used as an indicator of the severity of cardiac dysfunction [13] .
Surgical procedures
Of 141 patients, 119 (84%) received pulsatile extracorporeal LVADs (Nipro Co., Tokyo, Japan) and 22 (16%) received continuous flow LVADs, which were not commercially available until April 2011.
Tricuspid valve repair was performed by undersized ring annuloplasty or the de Vega annuloplasty procedure in 69 patients (49%) who had moderate-to-severe TR (Grade 3 or 4) or severe tricuspid annular dilatation >40 mm in diameter ( Table 2) . Choice of the de Vega method (n = 21, 30%) or annuloplasty ring (n = 48, 70%) was based on the era of the procedure, with a flexible ring (Cosgrove band, Duran ring) used in 32 patients and a semirigid ring (MC3) in 16. There was no significant difference in choice of procedure between the RVF and non-RVF groups. TVR was performed at the same time as LVAD implantation in 68 of the 69 patients. One patient underwent TVR 1 week after biventricular assist device implantation and was then weaned from the RVAD.
Statistical analysis
Differences between measures of continuous variables were analysed using an independent sample t-test for normal data and a Mann-Whitney U-test for non-normal data. For categorical variables, Fisher's exact test was used to compare two groups. Potential risk factors for RVF were examined by stepwise forward multivariate logistic regression using univariate predictors for RVF, with a P-value of <0.05 as the entry criterion. Patient survival analysis was performed using the Kaplan-Meier method, with actuarial differences evaluated with a log-rank test. Univariate and multivariate Cox hazard analyses were used to determine the risks for survival and hazard ratio, respectively. Patients were censored for transplantation and native heart recovery. All statistical analyses were performed using the JMP 8 statistical software package (SAS Institute, Inc., Cary, NC, USA). Table 1 shows preoperative characteristics of the RVF and non-RVF groups. Both groups had similar ages, body surface area, causes of heart failure, echocardiographic data except for TR grade (P = 0.006) and pulmonary artery catheter-based haemodynamics except for the CVP/PCWP ratio (P = 0.004). However, compared with patients in the non-RVF group, patients in the RVF group had more clinical symptoms and significantly more were at INTERMACS profile level 1 (P = 0.023) and supported by venoarterial extracorporeal membrane oxygenation (P = 0.004). The RVF group had significantly higher total bilirubin (P = 0.001) and creatinine (P = 0.036) than the non-RVF group, suggesting secondary multiorgan dysfunction due to congestive heart failure. Furthermore, the fibrosis score, graded from 0 to 3 based on the degree of fibrosis in a specimen obtained from the left ventricular apex, was significantly higher in the RVF group (P = 0.006).
RESULTS
Stepwise forward multivariate logistic regression revealed that preoperative TR grade (P = 0.034, hazard ratio = 1.90) and fibrosis grade (P = 0.048, hazard ratio = 2.48) were independent risk factors for RVF (Table 3 ). The two groups received similar devices for LVAD, and 67% of the RVF group and 45% of the non-RVF group underwent TVR (Table 3) .
One patient, who required a biventricular assist device, died within 1 month of implantation, for a 30-day mortality of 0.7%. The average LVAD support duration was 595 days. The 1-, 2-and 3-year survival rates while on LVAD were 86%, 75% and 54%, respectively (Fig. 1A) . Univariate Cox hazard analysis revealed that the CVP/PCWP ratio (hazard ratio = 4.32, P = 0.002), RVF (hazard ratio = 4.08, P < 0.001), preoperative venoarterial extracorporeal membrane oxygenation support (hazard ratio = 2.63, P = 0.002), creatinine level (hazard ratio = 1.39, P = 0.007) and TR grade (hazard ratio = 1.31, P = 0.042) had significant associations with long-term survival (Table 4 ). Furthermore, RVF was shown to be an independent risk factor for long-term survival, as the survival rates (P < 0.001) of the groups were significantly different (Fig. 1B) . Four patients required biventricular assist devices, and tricuspid valve repair was indicated in three of these. Only one of these patients who underwent tricuspid valve repair survived after weaning from the biventricular assist device.
We also compared patients who required tricuspid valve repair (n = 69) with those who did not (n = 72). Although the two groups had similar clinical conditions (INTERMACS profiles, need for ventilation, intra-aortic balloon pump or venoarterial extracorporeal membrane oxygenation), patients who required tricuspid valve repair had a greater TR grade as shown by echocardiography, greater elevation of CVP and higher CVP/PCWP ratio (Table 5 ). In addition, patients receiving tricuspid valve repair had a significantly higher creatinine level (P = 0.006) and significantly higher fibrosis score (P = 0.009) than those who did not receive tricuspid valve repair. These data suggest that right ventricular function was worse in patients who required tricuspid valve repair. Among the variables, three (creatinine, TR grade and CVP/PCWP ratio) were common risk factors for RVF, long-term survival and requirement for tricuspid valve repair. Although patients who required tricuspid valve repair had worse preoperative parameters than those who did not, the long-term survival rates were similar between the two groups (Fig. 1C) . We compared long-term survival among RVF patients who received tricuspid valve repair (n = 18) versus non-RVF patients who received tricuspid valve repair (n = 51; Fig. 1D ). Patients who developed RVF despite tricuspid valve repair had a significantly lower survival rate (P < 0.001).
Follow-up echocardiography examinations showed that TR grade was significantly decreased from 2.6 to 1.0 after tricuspid valve repair, a decrease that was maintained for 2 years (Fig. 2) .
DISCUSSION
The use of LVAD systems is no longer only a life-saving treatment, but also provides long-term survival with good quality-of-life for patients with severe heart failure. In this setting, right heart function becomes the key to patient survival, and RVF remains a significant postoperative complication that affects mortality. In our series, RVF reduced the 1-year survival rate from 91 to 65%, the 2-year survival rate from 83 to 43% and was shown to be an independent risk factor for long-term survival. Previously, the mechanisms of postoperative RVF were explained by acute unloading of the left ventricle, which leads to a septal shift that alters right ventricular shape and size, thereby affecting contractility [14] . However, underlying right ventricular impairment has also been reported to be unmasked with increased right ventricular preload [15] . Other studies have reported a variety of preoperative haemodynamic and laboratory measures as predictors of RVF, including decreased pulmonary artery pressure and right ventricular stroke work index, as well as elevated CVP and CVP/PCWP ratio, hepatic transaminases, total bilirubin and creatinine [5, [16] [17] [18] . Our findings support some of these variables as markers of right heart congestion. Elevated CVP is essential to maintain preload in patients with a deteriorated right ventricle that must eject against elevated pulmonary artery pressure, but leads to congestive liver and kidney dysfunction. Most patients with elevated CVP in our study developed secondary TR. TR is caused by annular dilatation and increased tricuspid leaflet tethering in relation to right ventricular dilatation that result from right ventricular pressure and/or volume overload [19, 20] . Pressure overload is most often caused by pulmonary hypertension resulting from left-sided heart disease. The 2012 guidelines of the European Society of Cardiology and European Association for Cardio-Thoracic Surgery note that TR may persist even after successful correction of left-sided lesions, while increased right ventricular dimension, reduced right ventricular function and severe tricuspid valve deformation, which are often observed in patients supported by LVAD, are important risk factors for persistence or late worsening of TR [21] . Furthermore, the guidelines recommend a grade of class I or IIa in patients with severe TR and in those with moderate or mild TR with a dilated annulus. LVAD implantation alone has been reported not to significantly improve TR immediately after surgery [7] . Therefore, concomitant tricuspid valve repair should be considered in patients with TR. Patients in our series who underwent tricuspid valve repair had impaired haemodynamic and laboratory values, including elevated CVP and CVP/ PCWP ratio, higher fibrosis score in the left ventricular apex myocardium and elevated creatinine. These factors are commonly associated with poor long-term survival or RVF. However, the survival rate of patients who underwent tricuspid valve repair was similar to that of patients who did not, indicating a survival benefit of tricuspid valve repair. With all tricuspid interventions, one key issue is correct operative indications. Tricuspid valve repair should be considered based not only on morphological changes of the tricuspid valve and annulus, but also on haemodynamic measurements such as CVP, CVP/PCWP ratio and trans-pulmonary pressure gradient, which are potent indicators of right ventricular status. Because tricuspid valve repair was performed in patients with adequate indications (49% underwent the procedure), survival in our study was as good as the latest INTERMACS continuous flow survival curve, despite the fact that 84% of our patients received pulsatile flow LVADs, which were associated with worse outcomes in that report [1] . TR does not resolve with mechanical left ventricular unloading and surgical risk is not increased by the addition of tricuspid valve repair procedures. Furthermore, the durability of tricuspid valve repair is remarkable, as shown by the unchanged TR grade for up to 2 years after surgery, presented in Fig. 2 . Therefore, concomitant tricuspid valve repair appears to be a useful and durable procedure for restoring deteriorated right ventricular function.
Despite undergoing tricuspid valve repair, some patients developed RVF and their long-term survival was significantly worse than that of patients who did not develop RVF, as shown in Fig. 1D . These results suggest that not only haemodynamic impairment, which can be resolved by tricuspid valve repair, but also structural deterioration may lead to RVF in some patients, and indicates the need for other strategies, such as earlier implantation of LVAD, to effectively treat RVF. In conclusion, RVF after LVAD implantation is sometimes unavoidable in a deteriorated heart. Careful evaluation of CVP, PCWP and laboratory data may help to predict postoperative RVF. To determine whether tricuspid valve repair is a useful manoeuvre to rescue patients from possible RVF, a randomized study is required. Nevertheless, our findings show that tricuspid valve repair is safe, durable and useful to prevent potential RVF and suggest that a proactive approach in determining indications for tricuspid valve repair should be considered in patients with possible RVF.
STUDY LIMITATIONS
This study was a retrospective analysis and did not randomize patients to receive tricuspid valve repair in conjunction with LVAD implantation, though patients who underwent tricuspid valve repair may have had worse right ventricular performance prior to LVAD implantation than those who did not. In addition, the situation may be slightly different in the present era of continuous flow LVAD, because our series contained a number of patients who received a pulsatile LVAD. Figure 2 : Echocardiography was performed before and after surgery. TR was graded from 0 to 4 (severe). Follow-up echocardiography examinations were performed at 1, 3, 6, 12, 18 and 24 months after implantation. All postoperative TR grades were significantly lower than preoperative TR grade in every patient who underwent TVR.
